NCT02174159View on ClinicalTrials.gov

Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 15, 2014

Primary Completion Date

July 16, 2015

Study Completion Date

July 23, 2015

Conditions
HIV-1 Infection
Interventions
DRUG

Ulonivirine

MK-8507 administered as a single oral dose

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02174159 - Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003) | Biotech Hunter | Biotech Hunter